NCT04348747 uses dendritic cell vaccines targeting HER2/HER3, and the combination with pembrolizumab can strengthen the immune system and enhance the tumor immune responses, which is favorable to shrinking cancer. This evidence concerns the gene ERBB3 and cancer.